Salvia reports successful first application for the treatment of severe migraines in humans

Salvia BioElectronics, a pioneering Dutch company specialising in the treatment and cure of severe migraines, announced the successful first implantation of its paper-thin neuromodulation solution.

Migraine is the most common cause of disability in people under 50 and affects one in seven people, mainly women. More than five percent of migraine patients suffer from chronic migraines, averaging of 22 headache days per month.

For the first time in the medical history, bioelectronic foils were implanted to treat severe migraines and cluster headaches. Salvia’s ultra-thin bioelectronic foil is surgically placed just under the skin and emits gentle electrical impulses to reduce the hypersensitivity of the nervous system. Salvia’s unique solution and the large unmet medical need it addresses were recognised by the US Food and Drug Administration (FDA), which granted Salvia Breakthrough Therapy designation in 2020.

Click here for the press release: link